Profile data is unavailable for this security.
About the company
TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing novel therapies for age-related diseases and autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. Supera-CBD is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the growing CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not currently regulated as drugs.
- Revenue in USD (TTM)0.00
- Net income in USD-7.07m
- Incorporated2023
- Employees9.00
- LocationTNF Pharmaceuticals Inc855 N. Wolfe Street, Suite 601BALTIMORE 21205United StatesUSA
- Websitehttps://tnfpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marizyme Inc | 549.70k | -69.02m | 4.14m | 11.00 | -- | -- | -- | 7.53 | -1.42 | -1.42 | 0.0081 | -0.0822 | 0.0184 | 1.65 | 14.06 | 49,972.73 | -230.68 | -59.02 | -531.63 | -64.47 | 71.17 | 70.38 | -12,555.69 | -9,435.92 | 0.0279 | -0.5837 | 1.92 | -- | 176.59 | 99.98 | -71.22 | -- | -- | -- |
| Trevena Inc | 3.14m | -40.15m | 4.15m | 23.00 | -- | -- | -- | 1.32 | -2.71 | -2.71 | 0.2107 | -0.7999 | 0.0904 | -- | -- | 136,478.30 | -115.65 | -55.93 | -148.14 | -66.35 | 48.04 | -- | -1,279.01 | -3,134.41 | -- | -15.39 | 1.88 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Exicure Inc | 500.00k | -13.34m | 4.15m | 6.00 | -- | 1.88 | -- | 8.31 | -1.56 | -1.56 | 0.0582 | 0.2551 | 0.0289 | -- | -- | 83,333.34 | -76.97 | -41.52 | -91.14 | -55.78 | -- | -- | -2,667.20 | -290.95 | -- | -- | 0.00 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| Axim Biotechnologies Inc | 85.35k | -5.59m | 4.31m | 6.00 | -- | -- | -- | 50.54 | -0.0249 | -0.0249 | 0.0003 | -0.0268 | 0.0214 | -- | -- | 14,225.00 | -140.13 | -154.34 | -- | -390.73 | -- | -- | -6,548.75 | -36,362.71 | -- | -1.16 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -897.69k | 4.33m | 3.00 | -- | -- | -- | -- | -0.1245 | -0.1245 | 0.00 | -0.8498 | 0.00 | -- | -- | 0.00 | -789.46 | -- | -- | -- | -- | -- | -- | -- | -- | -26.91 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -9.60m | 4.36m | 5.00 | -- | 0.4571 | -- | -- | -3.13 | -3.13 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -66.62 | -- | -70.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| TNF Pharmaceuticals Inc | 0.00 | -7.07m | 4.43m | 9.00 | -- | 0.1959 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -11.24m | 4.44m | 4.00 | -- | 0.6955 | -- | -- | -6.01 | -3.75 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -212.33 | -182.35 | -273.26 | -235.45 | -- | -- | -- | -- | -- | -20.20 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Soligenix Inc | 699.21k | -7.01m | 4.47m | 13.00 | -- | 3.88 | -- | 6.40 | -11.83 | -11.83 | 1.16 | 1.17 | 0.073 | -- | 4.17 | 53,785.38 | -73.17 | -75.40 | -2,448.34 | -154.32 | 9.46 | 22.83 | -1,002.55 | -620.02 | -- | -- | 0.7959 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 4.58m | 3.00 | 3.10 | -- | 180.46 | 16.28 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -38.52m | 4.61m | 22.00 | -- | 0.7468 | -- | -- | -9.49 | -9.49 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -117.64 | -61.43 | -145.05 | -68.82 | -- | -- | -- | -- | -- | -3,240.31 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 2.83m | -10.03m | 4.68m | 17.00 | -- | 0.3926 | -- | 1.65 | -64.14 | -64.14 | 4.60 | 3.82 | 0.2041 | 2.69 | 7.77 | 166,299.40 | -72.67 | -80.65 | -107.67 | -224.84 | 23.33 | -- | -356.09 | -948.54 | 1.87 | -- | 0.0451 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
| Viaderma Inc | 17.80m | 2.31m | 4.68m | 75.00 | 0.0002 | 0.00001 | 0.8654 | 0.2631 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
| Oragenics Inc | 20.63k | -20.26m | 4.73m | 5.00 | -- | 4.58 | -- | 229.14 | -7.98 | -7.98 | 0.0079 | 0.5859 | 0.0026 | -- | -- | 4,126.00 | -258.71 | -97.60 | -312.34 | -106.24 | -- | -- | -98,214.93 | -36,169.75 | -- | -- | 0.0461 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
Data as of Jul 26 2024. Currency figures normalised to TNF Pharmaceuticals Inc's reporting currency: US Dollar USD
38.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Global X Management Co. LLCas of 31 Mar 2024 | 875.93k | 36.95% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 30.35k | 1.28% |
| Iroquois Capital Management LLCas of 24 May 2024 | 6.72k | 0.28% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.56k | 0.28% |
| UBS Securities LLCas of 31 Mar 2024 | 1.96k | 0.08% |
| Parallel Advisors LLCas of 31 Mar 2024 | 838.00 | 0.04% |
| Group One Trading LPas of 31 Mar 2024 | 459.00 | 0.02% |
| Vanguard Global Advisers LLCas of 31 Mar 2024 | 310.00 | 0.01% |
| BlackRock Investment Management LLCas of 31 Mar 2024 | 247.00 | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 224.00 | 0.01% |
More ▼
Data from 31 Mar 2024 - 11 Jul 2024Source: FactSet Research Systems Inc.
